Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bedaquiline + rifampicin (Institute of Tropical Medicine Antwerp)
- Development stage
- Unknown
- Lead developer
- Institute of Tropical Medicine Antwerp
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**BE-PEP** is an investigational oral post-exposure prophylaxis regimen comprising **bedaquiline plus rifampicin** for prevention of leprosy among contacts of newly diagnosed leprosy cases. The regimen was developed by the Institute of Tropical Medicine as an enhanced alternative to WHO-recommended single-dose rifampicin prophylaxis. Bedaquiline inhibits mycobacterial ATP synthase, depleting cellular energy production, while rifampicin inhibits DNA-dependent RNA polymerase and thereby suppresses bacterial RNA synthesis. BE-PEP is being evaluated in the BE-PEOPLE program in the Comoros, including a Phase 3 cluster-randomized study comparing the regimen with standard single-dose rifampicin prophylaxis.
- Other names
- BE-PEPBedaquiline Enhanced Post ExpOsure Prophylaxisbedaquiline + rifampicin
02
Targets
AtpE (ATP synthase subunit c of Mycobacterium tuberculosis)rpoB (DNA-directed RNA polymerase subunit beta)PXR (Pregnane X receptor)AtpC (ATP synthase epsilon subunit)
Beyond the preview
Go deeper on bedaquiline + rifampicin (Institute of Tropical Medicine Antwerp).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bedaquiline + rifampicin (Institute of Tropical Medicine Antwerp).